Outcomes of Clinical Trials on Osteonecrosis of the Jaw.
bisphosphonate-related osteonecrosis of the jaw
bronj
clinical trials
medication-related osteonecrosis of the jaw
mronj
nct
ornj
osteoradionecrosis of the jaw
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
10
08
2020
accepted:
14
09
2021
entrez:
18
10
2021
pubmed:
19
10
2021
medline:
19
10
2021
Statut:
epublish
Résumé
The purpose of this study was to provide a cross-sectional view of all registered clinical trials enrolling patients with osteonecrosis of the jaw (ONJ). The primary aim was to report predictors of trial completion and publication of results. This is a cross-sectional study of ONJ trials registered with ClinicalTrials.gov. For each included entry, trial characteristics and endpoints were recorded. Predictors were enrollment size, etiology, study type, intervention type, sponsor, funding, study locations, number of centers, and specialty of the principal investigator. Outcomes were trial status, publication on PubMed, journal of publication, and length of time between endpoints. Associations between predictors and outcomes were evaluated using chi-square tests and t-tests. The final sample included 26 trials. Overall, 50% of trials were completed and 69% of completed trials were published. Three out of four terminated trials were suspended due to lack of funding. The median enrollment for completed trials was 149 participants with a mean length of five years. All trials included medication-related osteonecrosis of the jaw (MRONJ) patients and 26% also included osteoradionecrosis of the jaw (ORNJ) patients. The majority of trials were observational (65%), conducted internationally (62%), and involved multiple centers (54%). Published trials had a mean time of 5.9 years between trial start and publication, which was comparable to trial length (p=0.90) and appeared in either dental (44%) or cancer (56%) journals. Completion and publication rates were not significantly increased by industry sponsorship/funding, larger enrollment sizes, or multi-center involvement. Oral and maxillofacial surgery was the most represented dental specialty of principal investigators (56%). The majority of completed ONJ trials had their results published in a timely manner. Evidence-based investigation of ONJ is a multi-disciplinary and international effort. Among all specialists, oral and maxillofacial surgeons led the most ONJ trials.
Identifiants
pubmed: 34660159
doi: 10.7759/cureus.17984
pmc: PMC8516017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e17984Informations de copyright
Copyright © 2021, Wu et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2014 Dec 23;9(12):e114023
pubmed: 25536072
J Oral Maxillofac Surg. 2014 Feb;72(2):306-10
pubmed: 24075237
JAMA Otolaryngol Head Neck Surg. 2020 Feb 1;146(2):176-182
pubmed: 31876933
J Back Musculoskelet Rehabil. 2018 Feb 6;31(1):45-48
pubmed: 28826165
Trials. 2018 May 3;19(1):267
pubmed: 29724229
Support Care Cancer. 2017 Apr;25(4):1191-1199
pubmed: 27928641
PLoS One. 2019 Jul 10;14(7):e0219458
pubmed: 31291350
Support Care Cancer. 2018 Jun;26(6):1905-1915
pubmed: 29275525
J Oral Maxillofac Surg. 2012 Jul;70(7):1573-83
pubmed: 22698292
J Oral Maxillofac Surg. 2015 Mar;73(3):377
pubmed: 25683041
J Oral Maxillofac Surg. 2019 Aug;77(8):1655.e1-1655.e17
pubmed: 31108060
J Dent Res. 2011 Apr;90(4):433-8
pubmed: 21317245
J Dent Res. 2011 Apr;90(4):439-44
pubmed: 21317246
Eur J Cancer Care (Engl). 2018 Mar;27(2):e12638
pubmed: 28134499
J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
pubmed: 12966493
Mol Oncol. 2015 Nov;9(9):1868-76
pubmed: 26276228
Support Care Cancer. 2015 Jan;23(1):21-8
pubmed: 24939674
Imaging Sci Dent. 2017 Mar;47(1):45-50
pubmed: 28361029
PLoS Med. 2009 Sep;6(9):e1000144
pubmed: 19901971